Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Phase 1

Not yet recruiting

Conditions: Lymphoma, T-Cell

Interventions: Drug: GCC2005
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-25

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 48

Registration Number: NCT06699771

Locations: 🇰🇷
Seoul National University Hosptial, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Early Phase 1

Recruiting

Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions: Biological: QH10304-BAL-01
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 18

Registration Number: NCT06696833

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu, China

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2

Not yet recruiting

Conditions: Gastrointestinal Carcinoma
Pancreatic Cancer
Hepatocellular Cancer
Cholangiocarcinoma
Duodenal Cancer
Colorectal Cancer
Small Bowel Cancer
Metastatic Cancers

Interventions: Biological: KRAS TCR-Transduced PBL
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT06690281

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Study of ARD103 CAR-T Therapy for Patients with R/R AML or MDS

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
MDS (Myelodysplastic Syndrome)

Interventions: Biological: ARD103
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: ARCE Therapeutics, Inc.

Target Recruit Count: 49

Registration Number: NCT06680752

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Phase 2

Not yet recruiting

Conditions: Acute Myelogenous Leukemia
Acute Lymphatic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Myelodysplastic Syndrome Other
Chronic Myelomonocytic Leukemia
Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation
Biological: Double Umbilical Cord Transplant
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Abatacept

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: Leland Metheny

Target Recruit Count: 20

Registration Number: NCT06680661

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1

Not yet recruiting

Conditions: Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Non-Active Secondary Progressive Multiple Sclerosis
Non-Active SPMS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Demyelinating Diseases
Immune System Diseases

Interventions: Drug: IDP-023
Drug: Ocrelizumab
Drug: Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Indapta Therapeutics, INC.

Target Recruit Count: 34

Registration Number: NCT06677710

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
🇺🇸
Stanford University, Stanford, California, United States

and more 1 locations